Hisamitsu Pharmaceutical will implement a share consolidation on May 13, 2026, reducing the number of issued shares from 70,401,547 shares to 3 shares. Delisting is scheduled for May 11, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4530","jir_company_name":"Hisamitsu Pharmaceutical Co., Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4530-20260417-01.pdf","jir_short_summary":"Hisamitsu Pharmaceutical will implement a share consolidation on May 13, 2026, reducing the number of issued shares from 70,401,547 shares to 3 shares. Delisting is scheduled for May 11, 2026.","jir_summary":"### Overview of Share Consolidation and Amendments to the Articles of Incorporation\nAt an extraordinary general meeting held on April 17, 2026, Hisamitsu Pharmaceutical Co., Inc. approved a proposal to consolidate ordinary shares at a ratio of 23,467,182 shares into 1 share, along with partial amendments to the Articles of Incorporation including the abolition of the unit share system. Consequently, the total number of issued shares will decrease from 70,401,547 shares to 3 shares, and the total number of authorized shares will be changed to 12 shares. The effective date of the share consolidation is scheduled for May 13, 2026.\n\n### Delisting and Impact on Shareholders\nFollowing the share consolidation, the company\u2019s shares will be delisted from the Tokyo Stock Exchange Prime Market, Nagoya Stock Exchange Premier Market, and Fukuoka Stock Exchange Main Market as of May 11, 2026. Trading on these markets will no longer be possible after the delisting date. Fractional shares arising from the consolidation will be purchased by the tender offeror, and the proceeds will be distributed to shareholders. Funds for purchasing these fractional shares are secured through loans from Sumitomo Mitsui Banking Corporation and Mitsubishi UFJ Bank.","jir_financial_highlights":"Consolidation Ratio: 1 share for every 23,467,182 shares (Issued shares reduced from 70,401,547 shares to 3 shares)\nTotal Number of Issued Shares (Before Effective Date): 70,401,547 shares (Number after cancellation of 4,763,348 treasury shares)\nTotal Number of Issued Shares (After Effective Date): 3 shares (Significant decrease)\nDelisting Date: Scheduled for May 11, 2026 (Start date of designated securities due to delisting is April 17, 2026)","jir_category":"","jir_hashtags":"#HisamitsuPharmaceutical, #CapitalPolicy, #ShareConsolidation, #Delisting, #JapaneseStocks","jir_key_figures":"Share Consolidation Ratio: 1 share for every 23,467,182 shares\nTotal Number of Issued Shares (Before Effective Date): 70,401,547 shares\nTotal Number of Issued Shares (After Effective Date): 3 shares\nDelisting Date: Scheduled for May 11, 2026\nShare Consolidation Effective Date: Scheduled for May 13, 2026","jir_meta_title":"[Hisamitsu Pharmaceutical] Implementation of Share Consolidation and Abolition of Unit Share System\uff5cMay 2026","jir_meta_description":"Hisamitsu Pharmaceutical will implement a share consolidation on May 13, 2026, reducing issued shares from 70,401,547 shares to 3 shares. Delisting is scheduled for May 11, 2026. Fractional shares will be purchased by the tender offeror and proceeds distributed to shareholders.","jir_og_title":"[Hisamitsu Pharmaceutical] Implementation of Share Consolidation and Abolition of Unit Share System\uff5cMay 2026","jir_og_description":"Hisamitsu Pharmaceutical will carry out a share consolidation in May 2026, with scheduled delisting. Distribution of proceeds from fractional shares to shareholders is also planned.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8125,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-41276","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n